ADVR: At less than $1/share price, and in fact at its current levels of .37-.57/share, the stock may be worth taking a serious look at.
At this point the science looks interesting and promising and the product R market value is high. Product R inhibits the production of key receptors for the HIV virus and hence may prevent the HIV virus from gaining entry into the cell. However, there is only one product, and its basically at the research stage moving towards an IND. The probability of success increases as a pharmaceutical achieves IND approval to go into man and then gets better as the product eventually moves up into the more advanced phases of clinical trials. That said, right now for ADVR, possible future cash flows from product R, can be deeply discounted.
However, one can also look at the management of the company, the scientists involved, intellectual property status, pre-clinical findings, etc., and throw this into the analytic mix. Taking all this into consideration which isn't easy to do for an early stage company, to me at current ADVR price levels, I don't think the stock is overvalued, and there is a good chance that ADVR may be worth more. We of course can only know this with more certainty when more news is forthcoming. However, a few hundred or a thousand shares at the current price, would not be risking a lot of money right now.
Please read the ADVR profile if interested and any further due diligence on ADVR that anyone can dig up, at least will be very helpful and greatly appreciated by me. Please see below on some of the information that I have right now.
Regards,
Jake Blackmerlin
"Advanced Viral Research Corp. Unveils Corporate
Website: www.adviral.com
New Site Offers Valuable Resource for Investors, Researchers and the Media
YONKERS, N.Y.--(BW HealthWire)--May 15, 2000--Advanced Viral Research Corp. (OTC
BB: ADVR) today unveiled its new corporate Web site at adviral.com.
The easy-to-navigate site features information on the company, its mission and scientific data on its
flagship drug in development, Product R.
Product R is a non-toxic peptide nucleic acid (PNA) immunomodulator, being developed by the
company as a broad-spectrum antiviral drug. The drug shows promise for the treatment of viral
infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases, such as
rheumatoid arthritis. PNAs are stable analogues of genes and have applications as genomics.
Advanced Viral Research Corp. laboratory studies have shown that Product R inhibits the
production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for
the human immunodeficiency virus (HIV).
"We can now quickly share our latest news and scientific research findings, on Product R and other
therapeutics under development, with members of the scientific and financial communities and the
media," said Shalom Z. Hirschman, M.D., President and Chief Executive Officer of Advanced Viral
Research Corp. "Our new Web site will be a valuable informational resource as our scientists
continue to conduct important research with Product R and as we progress towards our objectives,
including filing Investigational New Drug (IND) applications with the FDA."
The new site features links on company history, news releases, basic research findings, results of
clinical studies, biographical sketches of key personnel and an overview of the Advanced Viral
Research Institute -- where teams of molecular biologists, immunologists and biopolymer chemists
conduct biomedical research in an academically oriented environment.
"Future site plans include animated presentations of the Research Institute's scientific findings, such as
how viruses attack cells and how Product R helps stimulate cellular responses against viral infections.
We will also feature timely commentaries about medical research areas addressed by our scientists,"
said Dr. Hirschman. "Our Web site will be updated regularly and it will be a premier source of
information about our company and its science."
About The Advanced Viral Research Institute
Advanced Viral Research Corp.'s foundation begins with a dedication to scientific research and
cutting-edge innovation. In that spirit, the company created The Advanced Viral Research Institute to
foster individual scientific inquiry and creativity. Recent successes include identifying Product R's
mechanisms of action, which will help with the company's planned IND applications to the FDA.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm
committed to researching, developing and bringing to market new, effective therapies for viral and
other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its
flagship drug, Product R, is a non-toxic immunomodulator that has been shown to have beneficial
therapeutic effects against viral diseases such as AIDS.
Note: This news release contains forward-looking statements that involve risks associated with
clinical development, regulatory approvals, including application to the FDA, product
commercialization and other risks described from time to time in the SEC reports filed by ADVR.
Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies
of any other countries.
Contact:
Bratskeir & Company
Mike Rosen / Jill Miller,
212/679-2233
mrosen@bratskeir.com
jmiller@bratskeir.com" |
